API | carphenazine

carphenazine (proketazine) Report issue

Small molecule Approved ^FDA

ChEMBL DrugBank Drug Central Drugs@FDA KEGG PubChem

Active Ingredient History

NOW

Carfenazine (brand name Proketazine) is an antipsychotic and tranquilizer of the phenothiazine group. It is used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients. Proketazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. The following is a list of possible side effects that may occur from all constituting ingredients of Proketazine: akathisia, tardive dyskinesia, extrapyramidal symptoms, allergic purpura. ^NCATS

Chemistry

SMILES: CCC(=O)c1ccc2Sc3ccccc3N(CCCN4CCN(CCO)CC4)c2c1
InChIKey: XZSMZRXAEFNJCU-UHFFFAOYSA-N
Mol. Mass: 425.6
ALogP: 3.88 Partition coefficient
ChEMBL Molecules:

carphenazine

carphenazine maleate

More Chemistry

Pharmacology

Mechanisms of Action:
- D(2) dopamine receptor (Homo sapiens) ^UniProt
- 5-hydroxytryptamine receptor 2A (Homo sapiens) ^UniProt
- 5-hydroxytryptamine receptor 2C (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Discontinued
Delivery Methods: Oral
Pro Drug: No

Organizations (2)

Research & Development (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (1)

Schizophrenia

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue